S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.87 (-0.30%)
MSFT   318.05 (+2.56%)
FB   316.11 (+0.09%)
GOOGL   2,799.98 (+0.50%)
TSLA   1,036.42 (+1.77%)
AMZN   3,383.84 (+0.23%)
NVDA   244.50 (-1.08%)
BABA   171.23 (+0.73%)
NIO   40.54 (+0.17%)
CGC   13.22 (+0.38%)
GE   106.22 (-1.14%)
AMD   124.67 (+1.42%)
MU   68.08 (-1.25%)
T   25.37 (+0.00%)
F   15.60 (-2.13%)
ACB   7.05 (+0.28%)
DIS   171.39 (-0.38%)
PFE   43.26 (-0.69%)
BA   211.13 (+0.63%)
AMC   36.11 (+0.17%)
S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.87 (-0.30%)
MSFT   318.05 (+2.56%)
FB   316.11 (+0.09%)
GOOGL   2,799.98 (+0.50%)
TSLA   1,036.42 (+1.77%)
AMZN   3,383.84 (+0.23%)
NVDA   244.50 (-1.08%)
BABA   171.23 (+0.73%)
NIO   40.54 (+0.17%)
CGC   13.22 (+0.38%)
GE   106.22 (-1.14%)
AMD   124.67 (+1.42%)
MU   68.08 (-1.25%)
T   25.37 (+0.00%)
F   15.60 (-2.13%)
ACB   7.05 (+0.28%)
DIS   171.39 (-0.38%)
PFE   43.26 (-0.69%)
BA   211.13 (+0.63%)
AMC   36.11 (+0.17%)
S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.87 (-0.30%)
MSFT   318.05 (+2.56%)
FB   316.11 (+0.09%)
GOOGL   2,799.98 (+0.50%)
TSLA   1,036.42 (+1.77%)
AMZN   3,383.84 (+0.23%)
NVDA   244.50 (-1.08%)
BABA   171.23 (+0.73%)
NIO   40.54 (+0.17%)
CGC   13.22 (+0.38%)
GE   106.22 (-1.14%)
AMD   124.67 (+1.42%)
MU   68.08 (-1.25%)
T   25.37 (+0.00%)
F   15.60 (-2.13%)
ACB   7.05 (+0.28%)
DIS   171.39 (-0.38%)
PFE   43.26 (-0.69%)
BA   211.13 (+0.63%)
AMC   36.11 (+0.17%)
S&P 500   4,580.44 (+0.12%)
DOW   35,760.55 (+0.01%)
QQQ   381.05 (+0.51%)
AAPL   148.87 (-0.30%)
MSFT   318.05 (+2.56%)
FB   316.11 (+0.09%)
GOOGL   2,799.98 (+0.50%)
TSLA   1,036.42 (+1.77%)
AMZN   3,383.84 (+0.23%)
NVDA   244.50 (-1.08%)
BABA   171.23 (+0.73%)
NIO   40.54 (+0.17%)
CGC   13.22 (+0.38%)
GE   106.22 (-1.14%)
AMD   124.67 (+1.42%)
MU   68.08 (-1.25%)
T   25.37 (+0.00%)
F   15.60 (-2.13%)
ACB   7.05 (+0.28%)
DIS   171.39 (-0.38%)
PFE   43.26 (-0.69%)
BA   211.13 (+0.63%)
AMC   36.11 (+0.17%)
NASDAQ:EPIX

ESSA Pharma Stock Forecast, Price & News

$8.97
+0.05 (+0.56 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.64
$9.01
50-Day Range
$7.76
$15.86
52-Week Range
$5.40
$36.00
Volume126,687 shs
Average Volume380,964 shs
Market Capitalization$394.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56
30 days | 90 days | 365 days | Advanced Chart
Receive EPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.


ESSA Pharma logo

About ESSA Pharma

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPIX
Phone
N/A
Employees
25
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.47 per share

Profitability

Net Income
$-23.44 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$394.54 million
Next Earnings Date
12/21/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

210th out of 1,363 stocks

Pharmaceutical Preparations Industry

90th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions

Is ESSA Pharma a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ESSA Pharma stock.
View analyst ratings for ESSA Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than ESSA Pharma?

Wall Street analysts have given ESSA Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ESSA Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, December 21st 2021.
View our earnings forecast for ESSA Pharma
.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) issued its quarterly earnings results on Sunday, August, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.05.
View ESSA Pharma's earnings history
.

How has ESSA Pharma's stock been impacted by Coronavirus?

ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EPIX stock has increased by 120.4% and is now trading at $8.97.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EPIX?

5 brokerages have issued twelve-month target prices for ESSA Pharma's stock. Their forecasts range from $17.00 to $50.00. On average, they anticipate ESSA Pharma's share price to reach $30.25 in the next twelve months. This suggests a possible upside of 237.2% from the stock's current price.
View analysts' price targets for ESSA Pharma
or view top-rated stocks among Wall Street analysts.

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the following people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 71, Pay $788.6k)
  • Mr. Peter A. Virsik M.B.A., M.S., Exec. VP & COO (Age 50, Pay $615.59k)
  • Dr. Alessandra Cesano M.D., Ph.D., Chief Medical Officer
  • Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer (Age 64)
  • Chandtip Chandhasin, Exec.
  • Erica Osbourne, Exec.
  • Erin Rudsinski, Exec.
  • Leah Dimascio, Exec.
  • Loleta Harris, Exec.
  • Neil Thapar, Exec.

What other stocks do shareholders of ESSA Pharma own?

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $8.97.

How much money does ESSA Pharma make?

ESSA Pharma has a market capitalization of $394.54 million. The company earns $-23.44 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does ESSA Pharma have?

ESSA Pharma employs 25 workers across the globe.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is www.essapharma.com.

Where are ESSA Pharma's headquarters?

ESSA Pharma is headquartered at 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.